CR20220189A - Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. - Google Patents
Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.Info
- Publication number
- CR20220189A CR20220189A CR20220189A CR20220189A CR20220189A CR 20220189 A CR20220189 A CR 20220189A CR 20220189 A CR20220189 A CR 20220189A CR 20220189 A CR20220189 A CR 20220189A CR 20220189 A CR20220189 A CR 20220189A
- Authority
- CR
- Costa Rica
- Prior art keywords
- dry powder
- powder formulations
- tslp
- methods
- thymic stromal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La tecnología de la presente se relaciona, en general, con formulaciones en polvo seco de anticuerpos específicos para la linfopoyetina estromal tímica (TSLP), así como también métodos para tratar asma, con el uso de formulaciones en polvo seco, convenientemente vía administración pulmonar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962926833P | 2019-10-28 | 2019-10-28 | |
PCT/EP2020/080201 WO2021083908A1 (en) | 2019-10-28 | 2020-10-27 | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220189A true CR20220189A (es) | 2022-08-19 |
Family
ID=73030137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220189A CR20220189A (es) | 2019-10-28 | 2020-10-27 | Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. |
Country Status (16)
Country | Link |
---|---|
US (2) | US11904053B2 (es) |
EP (1) | EP4051708A1 (es) |
JP (1) | JP2022554249A (es) |
KR (1) | KR20220088752A (es) |
CN (1) | CN114867748A (es) |
AR (1) | AR120309A1 (es) |
AU (1) | AU2020376222A1 (es) |
BR (1) | BR112022008031A2 (es) |
CA (1) | CA3154999A1 (es) |
CL (1) | CL2023003432A1 (es) |
CO (1) | CO2022005391A2 (es) |
CR (1) | CR20220189A (es) |
IL (1) | IL292437A (es) |
MX (1) | MX2022005083A (es) |
TW (1) | TW202131947A (es) |
WO (1) | WO2021083908A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112023021587A2 (pt) * | 2021-04-19 | 2023-12-19 | Medimmune Ltd | Fab anti-tslp com estabilidade melhorada, kit, composição, vetor, célula, método de produção e usos |
WO2023064770A1 (en) * | 2021-10-11 | 2023-04-20 | Board Of Regents, The University Of Texas System | Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100702878B1 (ko) | 1999-10-29 | 2007-04-04 | 넥타르 테라퓨틱스 | 개선된 분산성을 갖는 건조 분말 조성물 |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TW201643179A (zh) | 2015-03-11 | 2016-12-16 | 葛蘭素史克智慧財產發展有限公司 | Tslp結合蛋白 |
WO2017042701A1 (en) * | 2015-09-09 | 2017-03-16 | Novartis Ag | Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies |
EP3346987A1 (en) | 2015-09-09 | 2018-07-18 | Novartis AG | Targeted delivery of spray-dried formulations to the lungs |
HUE053914T2 (hu) | 2015-09-09 | 2021-07-28 | Novartis Ag | Csecsemõmirigy-stróma eredetû limfopoietinhez (TSLP-hez) kötõdõ ellenanyagok és az ellenanyagok alkalmazására szolgáló eljárások |
JOP20190243A1 (ar) * | 2017-04-12 | 2019-10-13 | Medimmune Llc | علاج الربو بجسم مضاد لـ tslp |
US20210069106A1 (en) | 2018-01-26 | 2021-03-11 | Novartis Ag | High dose delivery of inhaled therapeutics |
-
2020
- 2020-10-27 CN CN202080086052.9A patent/CN114867748A/zh active Pending
- 2020-10-27 KR KR1020227017241A patent/KR20220088752A/ko unknown
- 2020-10-27 CR CR20220189A patent/CR20220189A/es unknown
- 2020-10-27 WO PCT/EP2020/080201 patent/WO2021083908A1/en unknown
- 2020-10-27 US US17/081,821 patent/US11904053B2/en active Active
- 2020-10-27 IL IL292437A patent/IL292437A/en unknown
- 2020-10-27 JP JP2022525006A patent/JP2022554249A/ja active Pending
- 2020-10-27 EP EP20797753.9A patent/EP4051708A1/en active Pending
- 2020-10-27 AU AU2020376222A patent/AU2020376222A1/en active Pending
- 2020-10-27 MX MX2022005083A patent/MX2022005083A/es unknown
- 2020-10-27 BR BR112022008031A patent/BR112022008031A2/pt unknown
- 2020-10-27 AR ARP200102963A patent/AR120309A1/es unknown
- 2020-10-27 CA CA3154999A patent/CA3154999A1/en active Pending
- 2020-10-28 TW TW109137435A patent/TW202131947A/zh unknown
-
2022
- 2022-04-28 CO CONC2022/0005391A patent/CO2022005391A2/es unknown
- 2022-11-09 US US18/053,941 patent/US20230201120A1/en active Pending
-
2023
- 2023-11-19 CL CL2023003432A patent/CL2023003432A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230201120A1 (en) | 2023-06-29 |
CN114867748A (zh) | 2022-08-05 |
KR20220088752A (ko) | 2022-06-28 |
BR112022008031A2 (pt) | 2022-07-12 |
MX2022005083A (es) | 2022-07-19 |
TW202131947A (zh) | 2021-09-01 |
IL292437A (en) | 2022-06-01 |
US11904053B2 (en) | 2024-02-20 |
CL2023003432A1 (es) | 2024-05-17 |
JP2022554249A (ja) | 2022-12-28 |
CA3154999A1 (en) | 2021-05-06 |
EP4051708A1 (en) | 2022-09-07 |
CO2022005391A2 (es) | 2022-08-19 |
US20210121406A1 (en) | 2021-04-29 |
WO2021083908A1 (en) | 2021-05-06 |
AU2020376222A1 (en) | 2022-06-02 |
AR120309A1 (es) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502331A1 (en) | Treatment of asthma with anti-tslp antibody | |
MX2022005083A (es) | Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. | |
PH12015502169A1 (en) | Immunomodulatory properties of multipotent adult progenitor cells and uses thereof | |
EA201890655A1 (ru) | Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул | |
MX2020007945A (es) | Proteinas f del rsv estabilizadas y usos de las mismas. | |
WO2013006474A3 (en) | Requlatora t cells and methods of identifying and isolating them using cd6 -expression or the combination of cd4, cd25 and cd127 | |
MX2020013421A (es) | Composiciones de dióxido de silicio de carbono poroso biogénico, métodos de elaboracion y uso de estas. | |
SG179432A1 (en) | Procurement, isolation and cryopreservation of endometrial/menstrual cells | |
MX2019008872A (es) | Prevencion y tratamiento de da?o o enfermedad osea y cartilago. | |
MY170720A (en) | Antibody formulations | |
MX2018010828A (es) | Medio para formar colonias y uso de este. | |
MX2010001723A (es) | Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes. | |
PH12021551100A1 (en) | Dried biological compositions and methods thereof | |
MX2021012041A (es) | Metodos para promover la diferenciacion de celulas epiteliales timicas y progenitores de celulas epiteliales timicas de celulas madre pluripotentes, celulas resultantes y usos de estas. | |
WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
PH12018500747B1 (en) | Fly ash, cement composition, and method of preparing fly ash | |
MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
JOP20200250A1 (ar) | تركيبات aav، وطرق تحضيرها وطرق الاستخدام | |
MX2021005157A (es) | Composiciones, metodos para hacer y utilizar extracto de salvado de arroz. | |
MX2023004078A (es) | Proteinas f de hmpv estabilizadas por prefusion. | |
MX2021007160A (es) | Una semilla de planta artificial y usos de esta. | |
GB2514741A (en) | Composition for use as a paint binder | |
MX2019014867A (es) | Metodo para tratar un efecto secundario de la inmunoterapia. | |
AU2018276376A1 (en) | Cell culture methods | |
MX2021008983A (es) | Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos. |